MILESTONE: strona spółki
10.05.2023, 14:42
MMD Successful completion of epidural steroid injections (ESI) using the CompuFlo Epidural System Under New AMA CPT Guidelines for Artificial Intelligence (AI) Assisted Pain Management Surgery
The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company", “the Issuer"), today announced the successful completion of the first series of epidural steroid injections (ESI) using the CompuFlo Epidural System by physicians under the new American Medical Association (AMA) Current Procedural Terminology (CPT®) guidelines for AI-assisted analgesic epidural needle placement in patients.
The AMA’s new technology-specific Category III CPT® code, which came into effect in the CPT codebook on January 1, 2023, specifically covers technologies that “integrate AI to place an epidural needle.” The published and copyrighted guidelines further note that the technology must include real-time software to assist the physician by transmitting key data points, along with sensors to interpret epidural pressures, detail anatomical needle placement, and measure precise saline volume via software facilitating data transmission to an epidural system console screen. The Board of Directors of the Company is not aware of any systems, other than the CompuFlo Epidural System, that would meet these criteria. Additionally, the technology is backed by a broad portfolio of domestic and international patents. The Board of Directors of the Company is proud to announce that multiple physicians have now completed ESI procedures using the CompuFlo Epidural System under the new AMA CPT guidelines for AI-assisted epidural needle placement. This is an important milestone, as it further validates the medical importance of the CompuFlo Epidural System by these physicians in their plans of treatment. Specifically, the Company’ proprietary and highly accurate AI-assisted technology enhances both the efficacy and safety of pain management surgery. The Board of Directors of the Company believes that this data will play an important role as the Company seeks reimbursement for the CompuFlo Epidural System under the new CPT® code.
The AMA’s new technology-specific Category III CPT® code, which came into effect in the CPT codebook on January 1, 2023, specifically covers technologies that “integrate AI to place an epidural needle.” The published and copyrighted guidelines further note that the technology must include real-time software to assist the physician by transmitting key data points, along with sensors to interpret epidural pressures, detail anatomical needle placement, and measure precise saline volume via software facilitating data transmission to an epidural system console screen. The Board of Directors of the Company is not aware of any systems, other than the CompuFlo Epidural System, that would meet these criteria. Additionally, the technology is backed by a broad portfolio of domestic and international patents. The Board of Directors of the Company is proud to announce that multiple physicians have now completed ESI procedures using the CompuFlo Epidural System under the new AMA CPT guidelines for AI-assisted epidural needle placement. This is an important milestone, as it further validates the medical importance of the CompuFlo Epidural System by these physicians in their plans of treatment. Specifically, the Company’ proprietary and highly accurate AI-assisted technology enhances both the efficacy and safety of pain management surgery. The Board of Directors of the Company believes that this data will play an important role as the Company seeks reimbursement for the CompuFlo Epidural System under the new CPT® code.